東曜藥業-B(01875.HK):孫暉、張勍及谷學林各自獲委任爲獨立非執行董事
格隆匯3月12日丨東曜藥業-B(01875.HK)公告,自2025年3月12日起生效:(i)胡蘭因三年任期屆滿且因希望投入更多時間到其他事務而無意續任,故已辭任公司獨立非執行董事、審計與關聯方交易審覈委員會主席及提名委員會成員;(ii)張鴻仁因三年任期屆滿且因希望投入更多時間到其他事務而無意續任,故已辭任公司獨立非執行董事、審計與關聯方交易審覈委員會成員及薪酬委員會成員;(iii)汪德潛因三年任期屆滿且因希望投入更多時間到其他事務而無意續任,故已辭任公司獨立非執行董事、薪酬委員會成員、提名委員會成員及戰略及ESG委員會成員,
董事會欣然宣佈,(a)孫暉,(b)張勍及(c)谷學林(統稱"新任獨立非執行董事")各自已獲委任爲公司獨立非執行董事,自2025年3月12日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.